-- 专注于巴西黄金开采和开发的塞拉比黄金公司（Serabi Gold plc，AIM：SRB，TSX：SBI）在英国午后交易时段股价上涨4%，此前该公司公布了2026年第一季度的产量和运营亮点。 在运营亮点方面，塞拉比指出，第一季度黄金产量为12,042盎司，较2025年第一季度增长20%。截至2026年3月31日，该公司现金余额为6440万美元，而截至2025年12月31日为4920万美元。该公司表示，目前已无债务，并在本季度偿还了530万美元。 此外，Serabi还在Palito矿区启动了第四台球磨机的安装工作，预计将于2026年第四季度投入运营，届时年处理量将提升至33万吨。经过12个月的矿石分选成功，公司正在Coringa矿区进行作业方式的转型，从选择性露天采矿过渡到机械化分段采矿。Coringa矿区目前持有为期三年的GUIA许可证，该许可证将于2027年1月29日到期。 Serabi首席执行官Mike Hodgson表示：“两座矿山的运营状况良好。矿石分选机在2025年帮助我们实现了创纪录的年产量，再加上Coringa矿脉良好的地质连续性，使我们能够从选择性露天采矿过渡到更加机械化的分段露天采矿方法，从而在成本、产量和安全性方面都带来了诸多益处。Coringa矿区的机械化改造预计将于2026年第三季度完成。” Serabi股票昨天加拿大股市上涨了3.8%。
Related Articles
Asia
Fadu Returns to Profit in Q1 as Sales Triple; Shares Jump 14%
Fadu (KOSDAQ:440110) posted first-quarter net income of 10.2 billion won, rebounding from a net loss of 12.1 billion won a year earlier, according to a Monday filing with the Korea Exchange.The South Korean chipmaker's sales revenue surged 210% year over year to 59.5 billion won from 19.2 billion won.Shares of Fadu jumped nearly 14% in recent trade.
$KOSDAQ:440110
Asia
ASX Biggest Losers
Here are the 10 ASX-listed companies with the biggest losses on Monday.Wisetech (ASX:WTC): -3%, AU$42.79NexGen Energy (ASX:NXG): -3%, AU$17.26Telix Pharmaceuticals (ASX:TLX): -2%, AU$14.47Cochlear (ASX:COH): -2%, AU$94.76Paladin Energy (ASX:PDN): -2%, AU$12.28Origin Energy (ASX:ORG): -2%, AU$12.44EVT (ASX:EVT): -2%, AU$12.44Tuas (ASX:TUA): -2%, AU$5.97Ramsay Health Care (ASX:RHC): -2%, AU$39.15Southern Cross Gold (ASX:SX2): -2%, AU$11.07
$^AXJO$ASX:COH$ASX:EVT$ASX:NXG$ASX:ORG$ASX:PDN$ASX:RHC$ASX:SX2$ASX:TLX$ASX:TUA$ASX:WTC
Asia
Sun Pharmaceutical to Acquire US-Based Organon in $11.8 Billion Deal
Sun Pharmaceutical Industries (NSE:SUNPHARMA, BOM:524715) has agreed to acquire US-based Organon & Co in an all-cash deal at an enterprise valuation of $11.8 billion, according to a Monday filing to the Indian stock exchanges.Under the pact, Sun Pharmaceutical will buy all outstanding shares of Organon for $14.00 per share. It plans to fund the acquisition through a combination of available cash resources and committed financing from banks.The acquisition is estimated to boost Sun Pharmaceutical's revenues to $12.4 billion.Organon, which was spun off from Merck in 2021, specializes in women's health and biosimilars and has more than 70 products sold across 140 countries.The Organon buyout is part of Sun Pharmaceutical's strategy "of growing its Innovative Medicines business," according to Sun Pharma's statement.The transaction is subject to customary closing conditions, including receipt of required regulatory approvals andapproval by Organon stockholders.
$BOM:524715$NSE:SUNPHARMA